<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882592</url>
  </required_header>
  <id_info>
    <org_study_id>SCONE CP 01</org_study_id>
    <nct_id>NCT04882592</nct_id>
  </id_info>
  <brief_title>Noninvasive Spinal Neuromodulation Enables Locomotor Recovery in Individuals With Cerebral Palsy</brief_title>
  <official_title>Noninvasive Spinal Neuromodulation Enables Locomotor Recovery in Individuals With Cerebral Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SpineX Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SpineX Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing the effects of noninvasive spinal cord neuromodulation on improving function in&#xD;
      individuals with cerebral palsy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stepping overground or on a treadmill</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gross Motor Functional Measure (GMFM)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cerebral Palsy</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SCONE</intervention_name>
    <description>Noninvasive spinal cord neuromodulator</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) individuals above the age of 2 years of age and 2) diagnosed with cerebral palsy&#xD;
             (CP). The exclusion criteria included 1) children with selective dorsal root&#xD;
             rhizotomy, 2) intramuscular Botox injection in the preceding 12 months, 3) current&#xD;
             antispastic medications 4) unhealed fractures or contractures that would prevent them&#xD;
             from performing functional tasks and 5) tendon lengthening surgeries.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intramuscular Botox injection in the past 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Parag Gad, PhD</last_name>
    <phone>4082035061</phone>
    <email>parag@spinex.coc</email>
  </overall_contact>
  <location>
    <facility>
      <name>SpineX</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parag Gad, PhD</last_name>
      <phone>408-203-5061</phone>
      <email>parag@spinex.co</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

